Previous close | 14.66 |
Open | 14.68 |
Bid | 14.23 x 200 |
Ask | 14.37 x 200 |
Day's range | 14.31 - 14.68 |
52-week range | 3.94 - 17.83 |
Volume | |
Avg. volume | 531,529 |
Market cap | 746.594M |
Beta (5Y monthly) | 1.30 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Sophia Randolph, Chief Medical Officer of ALX Oncology Holdings Inc (NASDAQ:ALXO), sold 12,000 shares of the company on May 13, 2024.
The mean of analysts' price targets for ALX Oncology Holdings (ALXO) points to a 36.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Consistent with Analyst Projections Amidst Clinical Advancements